Received May 4, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (NO BRAND NAME) | UNKNOWN MANUFACTURER | UNK | UNK | — |
Guillain Barre Syndrome; This serious case was reported by a consumer via interactive digital media and described the occurrence of guillain barre syndrome in a male patient who received Herpes zoster (Shingles vaccine) for prophylaxis. On an unknown date, the patient received Shingles vaccine. On an unknown date, an unknown time after receiving Shingles vaccine, the patient experienced guillain barre syndrome (Verbatim: Guillain Barre Syndrome) (serious criteria GSK medically significant). The outcome of the guillain barre syndrome was resolved (duration 6 months). It was unknown if the reporter considered the guillain barre syndrome to be related to Shingles vaccine. The company considered the guillain barre syndrome to be unrelated to Shingles vaccine. Additional Information: GSK Receipt Date: 23-APR-2026 This case was reported via interactive digital media. The reporter reported that the Guillain Barre Syndrome was painful, but it was temporary. Sadly, the vaccine increases the chances of Guillain Barre Syndrome It happened a lot and it happened to the reporter's very healthy brother, and it took him 6 months to recover. The batch number was not provided, and we are unable to contact the reporter.; Sender's Comments: A case of Guillain Barre Syndrome (not meeting BC Criteria), unknown time after receiving Shingles vaccine in a male patient. Case lacks further information on time to onset, medical history, concurrent conditions and laboratory confirmation. Based on the available information a possible causality that the event was caused by the GSK product cannot be ascertained. Consent for further follow-up has not been received.